Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

ClinicalTrials.gov ID: NCT07029711

Public ClinicalTrials.gov record NCT07029711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss. This study is seeking participants who have: * at least 50% scalp hair loss due to alopecia areata. * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. * history of clinical response failure to alopecia areata treatment (for children in EU/UK only). All participants in this study will receive either study medicine (ritlecitinib) or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. One-third of participants will receive ritlecitinib higher dose, one-third participants will receive ritlecitinib lower dose, and one-third participants will receive placebo. The study medicine is a capsule that is taken by mouth. It is taken once each day at home. The study will compare the experiences of participants receiving ritlecitinib to participants receiving placebo. This will help see if ritlecitinib is safe and effective. Participants will take part in this study for 6 months. During this time, they will have 8 study visits at the study clinic. The study team will also call participants about 8 times over the phone.

Study identification

NCT ID
NCT07029711
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
208 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2025
Primary completion
Dec 1, 2026
Completion
Jan 5, 2027
Last update posted
Aug 25, 2026

2025 – 2027

United States locations

U.S. sites
31
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
UCI Dermatology Clinical Research Irvine California 92697
Southern California Clinical Research Santa Ana California 92701
Children's Hospital Colorado Aurora Colorado 80045
Children's National Medical Center Washington D.C. District of Columbia 20010
Pediatric Skin Research Miami Florida 33156
Endeavor Health Audiology -CHICAGO Chicago Illinois 60625
Endeavor Health Behavioral Health - Evanston Evanston Illinois 60201
Endeavor Health Clinical Operations Evanston Illinois 60201
Endeavor Health Audiology -LAKE BLUFF Lake Bluff Illinois 60044
Endeavor Health Audiology-NORTHBROOK Northbrook Illinois 60062
Endeavor Health Audiology-SKOKIE Skokie Illinois 60076
Endeavor Health Clinical Operations Skokie Illinois 60077
Endeavor Health Lab Services - Old Orchard Skokie Illinois 60077
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250
Kindred Hair and Skin Center Marriottsville Maryland 21104
Michigan Dermatology Institute Waterford Michigan 48328
Ear, Nose and Throat Consultants, LLC Omaha Nebraska 68144
Skin Specialists, PC dba Schlessinger MD Omaha Nebraska 68144
Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) Papillion Nebraska 68046
University of New Mexico Health Sciences Center Albuquerque New Mexico 87102
University of New Mexico-IDS Pharmacy Albuquerque New Mexico 87106
Northwest Dermatology Institute Portland Oregon 97210
Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania 17033
Medical University of South Carolina Department of Dermatology and Dermatologic Surgery Charleston South Carolina 29425
Dell Children's Medical Center Austin Texas 78723
Driscoll Children's Hospital Corpus Christi Texas 78411
3A Research - West Location El Paso Texas 79902
Austin Institute for Clinical Research Pflugerville Texas 78660
Texas Dermatology and Laser Specialists San Antonio Texas 78218
Children's Wisconsin Milwaukee Wisconsin 53226
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07029711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2026 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07029711 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →